<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="21940" end="21945" sStart="21788" offset="152" sid="r7.1.use.v.0721" wn="1" wnkey="use%2:34:01::" text="For co-culture experiments, 293T cells were transfected with either Xenopus Wnt-5a [ 45 ] , mouse Wnt-1 [ 49 ] , or CS2+ as control using the lipofectamine PLUS reagents (GIBCO BRL) as directed by the manufacturer." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-213X-3-2.anc" start="22116" end="22127" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" text="24 hours after transfection the Wnt-expressing 293T cells were &lt;b&gt;transferred&lt;/b&gt; to culture dishes seeded with C57mg cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="10289" end="10297" sStart="null" offset="27" sid="r11.refer.v.0734" wn="1" wnkey="refer%2:32:01::" text="The secreted form has been referred to as megakaryocyte potentiating factor (MPF) for its ability to stimulate the megakaryocyte colony forming activity of murine IL-3 in mouse bone marrow cell culture [ 23 24 ] . Mesothelin expression is induced in a variety of cancers including ovarian, pancreatic, lung, and cervical cancer [ 25 26 ] . The soluble portion of mesothelin has drawn attention as a potential serum tumor marker since it is highly over-expressed in patients with ovarian carcinomas and pancreatic adenocarcinomas [ 27 28 ] ." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-213X-3-2.anc" start="26718" end="26722" sStart="null" offset="0" sid="null" wn="1" wnkey="read%2:31:00::" text="All authors &lt;b&gt;read&lt;/b&gt; and approved the final manuscript." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="9008" end="9018" sStart="null" offset="3" sid="r10.particular.j.0774" wn="3" wnkey="particular%5:00:00:uncommon:00" text="In particular, we wanted to activate the function of these Wnts for short durations rather than relying on stable expression." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="15036" end="15044" sStart="null" offset="116" sid="r11.function.n.0231" wn="2" wnkey="function%1:07:00::" text="C57mg cells were chosen since they become transformed by ectopic expression of Wnt-1 and by loss of function of Wnt-5a [ 12 15 16 ] . In addition, Wnt-5a/Rfz-2 C57mg cells exhibited phenotypic differences from wt C57mg cells (see results)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="9681" end="9685" sStart="null" offset="44" sid="r9.fold.v.0681" wn="2147483645" wnkey="null" text="One gene, mesothelin, exhibited a 3-fold induction in C57mg cells treated with the Wnt-1 but not the Wnt-5a secreting 293T cells (Figure 1, panel A)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="7081" end="7085" sStart="null" offset="38" sid="r9.fold.v.0836" wn="2147483645" wnkey="null" text="Probe sets that underwent a 2-fold or greater change in the Wnt-ligand expressing cells compared to control cells were selected for further analysis." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="12904" end="12908" sStart="null" offset="82" sid="r9.fold.v.0274" wn="" wnkey="null" text="Supporting the co-culture data discussed above, SL-1 exhibited almost a 3-fold induction with isoproterenol treated Rfz-2/? 2 AR expressing C57mg cells but not wt C57mg cells treated with isoproterenol (Figure 1, panel B)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="26291" end="26298" sStart="null" offset="105" sid="r10.control.n.0332" wn="4" wnkey="control%1:09:02::" text="Relative normalized units were then compared between the experimental sample and its control." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="7968" end="7974" sStart="null" offset="149" sid="r10.common.j.0465" wn="3" wnkey="common%5:00:00:shared:00" text="The list of genes shows those that are specific to Wnt-5a/Rfz-2, differential between Wnt-5a/Rfz-2 and Wnt-1, specific to Wnt-1, and common to both Wnt-1 and Wnt-5a/Rfz-2." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="25324" end="25335" sStart="null" offset="4" sid="r11.combination.n.0932" wn="1" wnkey="combination%1:14:00::" text="The combination of forward and reverse primer concentrations was selected based on the presence of a single band only in the +RT sample." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="24904" end="24916" sStart="null" offset="157" sid="r11.combination.n.0954" wn="1" wnkey="combination%1:14:00::" text="Three concentrations of each of the forward and reverse primers were used, 50 nM, 300 nM, and 900 nM, to obtain nine different combinations." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="7273" end="7281" sStart="null" offset="56" sid="r9.appear.v.0808" wn="1" wnkey="appear%2:39:00::" text="Over 90 genes that repeated in both experiments appeared to change in the Wnt-expressing cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-3-2.anc" start="13099" end="13106" sStart="null" offset="5" sid="r9.appear.v.0652" wn="1" wnkey="appear%2:39:00::" text="SL-1 appears to be up-regulated by Wnt-5a and not Wnt-1 (Table 1and Figure 1, panel A)." />
  </sentences>
</list>